ATE358122T1 - Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungen - Google Patents

Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungen

Info

Publication number
ATE358122T1
ATE358122T1 AT05290275T AT05290275T ATE358122T1 AT E358122 T1 ATE358122 T1 AT E358122T1 AT 05290275 T AT05290275 T AT 05290275T AT 05290275 T AT05290275 T AT 05290275T AT E358122 T1 ATE358122 T1 AT E358122T1
Authority
AT
Austria
Prior art keywords
tnf
autoimmune diseases
inhibitors
treatment
present
Prior art date
Application number
AT05290275T
Other languages
English (en)
Inventor
Masakazu Ban
Hiroshi Suhara
Masato Horiuchi
Noriyoshi Yamamoto
Hiroshi Enomoto
Hiroyuki Inoue
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE358122T1 publication Critical patent/ATE358122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05290275T 2000-05-31 2001-05-31 Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungen ATE358122T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000162945 2000-05-31

Publications (1)

Publication Number Publication Date
ATE358122T1 true ATE358122T1 (de) 2007-04-15

Family

ID=18666780

Family Applications (4)

Application Number Title Priority Date Filing Date
AT05290274T ATE481385T1 (de) 2000-05-31 2001-05-31 (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren
AT05290275T ATE358122T1 (de) 2000-05-31 2001-05-31 Inhibitoren der tnf-alpha bildung zur behandlung von autoimmunerkrankungen
AT01934447T ATE374186T1 (de) 2000-05-31 2001-05-31 Tnf-alpha-produktions-inhibitoren
AT06076696T ATE448204T1 (de) 2000-05-31 2001-05-31 1-ä(adamantyl)alkylü-3- ä(pyridinyl)alkylüharnstoff-verbindungen als tnf- .alpha hemmer zur behandlung von autoimmunerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05290274T ATE481385T1 (de) 2000-05-31 2001-05-31 (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT01934447T ATE374186T1 (de) 2000-05-31 2001-05-31 Tnf-alpha-produktions-inhibitoren
AT06076696T ATE448204T1 (de) 2000-05-31 2001-05-31 1-ä(adamantyl)alkylü-3- ä(pyridinyl)alkylüharnstoff-verbindungen als tnf- .alpha hemmer zur behandlung von autoimmunerkrankungen

Country Status (15)

Country Link
US (5) US7098226B2 (de)
EP (4) EP1568692B1 (de)
JP (4) JP3867196B2 (de)
KR (2) KR100880698B1 (de)
CN (3) CN1307159C (de)
AT (4) ATE481385T1 (de)
AU (3) AU6067401A (de)
CA (2) CA2409741C (de)
CY (1) CY1107089T1 (de)
DE (4) DE60140495D1 (de)
DK (1) DK1302461T3 (de)
ES (4) ES2339141T3 (de)
NO (2) NO324472B1 (de)
PT (1) PT1302461E (de)
WO (1) WO2001092229A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1568692B1 (de) * 2000-05-31 2010-09-15 Santen Pharmaceutical Co., Ltd. (Pyridinyl)alkyl-Amide oder -Harnstoffe als TNF-alpha Bildung Inhibitoren
AU2002349621A1 (en) * 2001-11-30 2003-06-10 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7456222B2 (en) 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
US7652039B2 (en) 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
EP1670314A4 (de) 2003-09-05 2009-02-25 Sequella Inc Verfahren und zusammensetzungen enthaltend diamine als neue therapeutika für tuberkulose
WO2005102332A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 変形性関節症治療剤
WO2005102331A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 骨粗鬆症治療剤
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006035759A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 呼吸器疾患治療剤
WO2006035760A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 皮膚疾患治療剤
WO2006043518A1 (ja) * 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. 神経疾患治療剤
KR101496190B1 (ko) * 2005-01-05 2015-02-26 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101302627B1 (ko) * 2005-01-05 2013-09-10 아비에 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제
US8562629B2 (en) * 2006-10-24 2013-10-22 Arthrocare Corporation Suture device having selective needle actuation and related method
EP1935420A1 (de) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
JP5512948B2 (ja) * 2007-10-16 2014-06-04 参天製薬株式会社 Ｔｒｐｖ１媒介性疾患治療剤
KR101702142B1 (ko) * 2008-10-22 2017-02-03 아유미 세이야쿠 가부시키가이샤 장관 흡수성을 개선하는 의약 조성물
RU2404157C1 (ru) * 2009-02-16 2010-11-20 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения n-(1-адамантилалкил)циклоалкиламинов
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
KR101231412B1 (ko) * 2009-12-29 2013-02-07 실트로닉 아게 실리콘 웨이퍼 및 그 제조 방법
MX2016006325A (es) 2013-11-15 2016-12-02 Wistar Inst Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso.
EP3294705B1 (de) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Ebna1-inhibitoren und verfahren damit
WO2019222470A1 (en) 2018-05-17 2019-11-21 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CN110423216B (zh) * 2019-08-26 2021-01-05 浙江工业大学 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用
WO2024084056A1 (en) * 2022-10-21 2024-04-25 Etherna Immunotherapies Nv Ionizable lipids

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2640055A (en) * 1951-01-06 1953-05-26 Warner Hudnut Inc Amides
CH500979A (de) * 1967-02-16 1970-12-31 Shimamoto Takio Verfahren zur Herstellung von Pyridinmethylcarbamaten
US3682922A (en) 1969-01-16 1972-08-08 Searle & Co N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines
US4724235A (en) 1981-05-20 1988-02-09 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia
US4597902A (en) 1981-05-20 1986-07-01 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas
US4555515A (en) * 1985-02-25 1985-11-26 Stauffer Chemical Co. Pyridylpropyl carbamates as insect repellents
US5599944A (en) * 1987-03-24 1997-02-04 Bayer Aktiengesellschaft Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
FR2664269B1 (fr) 1990-07-05 1992-10-02 Roussel Uclaf Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173506A (en) 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
NZ242054A (en) * 1991-03-22 1993-11-25 British Tech Group Pyridine derivatives having a bridged alicyclic group; medicaments
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
MX9605218A (es) * 1994-04-29 1997-10-31 Pfizer Amidas aciclicas y ciclicas novedosas como mejoradores de liberacion de neurotransmisores.
CA2502764A1 (en) * 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
WO1997026250A1 (en) * 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
EP0948489A1 (de) * 1996-12-17 1999-10-13 Fujisawa Pharmaceutical Co., Ltd. Piperazin-verbindungen als mmp oder tnf inhibitoren
EP0903434B1 (de) 1997-09-17 2002-11-27 Lenzing Aktiengesellschaft Verfahren zur Behandlung von Cellulosefasern
ATE228590T1 (de) 1997-09-17 2002-12-15 Chemiefaser Lenzing Ag Verfahren zur behandlung von cellulosefasern
JP3603177B2 (ja) 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
EP1072591A4 (de) * 1998-03-26 2005-01-05 Santen Pharmaceutical Co Ltd Neue urea-verbindungen
EP1103543A4 (de) * 1998-08-05 2005-06-22 Santen Pharmaceutical Co Ltd Harnstoffderivate mit stickstoffhaltigen aromatischen heterocyclen
JP3472917B2 (ja) 1998-08-05 2003-12-02 参天製薬株式会社 含窒素芳香族複素環を有する新規ウレア誘導体
CA2362705A1 (en) * 1999-03-19 2000-09-28 Joseph B. Santella, Iii N-adamant-1-yl-n'-¬4-chlorobenzothiazol-2-yl| urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
WO2000061552A1 (en) 1999-04-07 2000-10-19 Santen Pharmaceutical Co., Ltd. N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-α PRODUCTION INHIBITOR
DE29910780U1 (de) * 1999-06-21 1999-09-16 Hahn Schickard Ges Halte- und Betätigungsvorrichtung
EP1568692B1 (de) * 2000-05-31 2010-09-15 Santen Pharmaceutical Co., Ltd. (Pyridinyl)alkyl-Amide oder -Harnstoffe als TNF-alpha Bildung Inhibitoren
AU2002349621A1 (en) 2001-11-30 2003-06-10 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor

Also Published As

Publication number Publication date
CN1324012C (zh) 2007-07-04
US20060241155A1 (en) 2006-10-26
EP1743885A2 (de) 2007-01-17
KR20030007762A (ko) 2003-01-23
KR100880698B1 (ko) 2009-02-02
AU2006200864B2 (en) 2007-12-06
ES2293993T3 (es) 2008-04-01
US7098226B2 (en) 2006-08-29
ATE374186T1 (de) 2007-10-15
WO2001092229A1 (fr) 2001-12-06
EP1568692A1 (de) 2005-08-31
US20030032623A1 (en) 2003-02-13
EP1302461B1 (de) 2007-09-26
US20080182881A1 (en) 2008-07-31
NO20025718D0 (no) 2002-11-28
AU2001260674B2 (en) 2006-03-30
PT1302461E (pt) 2007-12-13
CA2409741A1 (en) 2001-12-06
ES2353020T3 (es) 2011-02-24
ATE448204T1 (de) 2009-11-15
CA2409741C (en) 2011-11-01
CN1307159C (zh) 2007-03-28
AU6067401A (en) 2001-12-11
JP2010059205A (ja) 2010-03-18
DE60130658T2 (de) 2008-01-31
US7923461B2 (en) 2011-04-12
US7345064B2 (en) 2008-03-18
NO20073371L (no) 2002-11-28
DE60143098D1 (de) 2010-10-28
JP2010059204A (ja) 2010-03-18
DE60140495D1 (de) 2009-12-24
NO324472B1 (no) 2007-10-29
DE60127595T2 (de) 2008-01-10
KR20080093166A (ko) 2008-10-20
AU2006200864A1 (en) 2006-03-23
CN1284771C (zh) 2006-11-15
CN1590375A (zh) 2005-03-09
NO20025718L (no) 2002-11-28
EP1743885A3 (de) 2007-03-14
JP2002053555A (ja) 2002-02-19
ATE481385T1 (de) 2010-10-15
US20100016380A1 (en) 2010-01-21
EP1561749B1 (de) 2007-03-28
EP1302461A4 (de) 2004-05-26
JP4482735B2 (ja) 2010-06-16
DE60130658D1 (de) 2007-11-08
CN1590374A (zh) 2005-03-09
CA2736344A1 (en) 2001-12-06
JP2006213739A (ja) 2006-08-17
DK1302461T3 (da) 2008-01-28
DE60127595D1 (de) 2007-05-10
CY1107089T1 (el) 2012-10-24
EP1568692B1 (de) 2010-09-15
ES2339141T3 (es) 2010-05-17
CN1432000A (zh) 2003-07-23
KR100978304B1 (ko) 2010-08-26
EP1743885B1 (de) 2009-11-11
EP1561749A1 (de) 2005-08-10
JP3867196B2 (ja) 2007-01-10
US20060229342A1 (en) 2006-10-12
US7491739B2 (en) 2009-02-17
ES2284138T3 (es) 2007-11-01
EP1302461A1 (de) 2003-04-16

Similar Documents

Publication Publication Date Title
DE60127595D1 (de) Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
HUP0302943A2 (hu) Új heterociklusos vegyületek, előállításuk és alkalmazásuk gyógyszerekként, különösen antibakteriális szerekként
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
ATE339409T1 (de) Trizyklische verbindungen
ATE327230T1 (de) Piperidinverbindungen und diese enthaltenden medikamente
BG107120A (bg) Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства
WO1998003505A3 (en) Heterocyclic compounds, their production and use
BR9106819A (pt) Polimeros contendo unidades diester,processo para a preparacao de um polimero e compostos
DE602004026629D1 (de) Cyclopropanderivate und ihre pharmazeutische verwendung
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
NZ338016A (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
ATE250031T1 (de) Tricyclische kondensierte heterocyclische verbindungen zur behandlung von seniler demenz
NO20004092D0 (no) Cyklisk amidforbindelse
TNSN99218A1 (fr) Nouveaux composes azabicycliques a substitution heteroaryl- ethyl/benzisoxazole, leur procede de production et composition pharmaceutique les contenant.
EP0567090A3 (de)
EP1122252A4 (de) Stickstoffhaltige annelierte heterocyclen, verfahren zu ihrer herstellung und agentien, die diese enthalten
EA200200611A1 (ru) Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции
DE69528978D1 (de) Lactamverbindungen als Inhibitoren der Cholesterin-Esterase
ATE116650T1 (de) Sulfonylamin substituierte bizyklische hydroxansäurederivate.
DE60230652D1 (de) Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz
CA2364199A1 (fr) Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE250027T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ES8608482A1 (es) Un procedimiento para preparar bisarilamidas de n,n'-di(1 aminoalquil-2) alquilendiaminas.
ATE449760T1 (de) Nichtpeptidinhibitoren von matrixmetalloproteinasen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties